Newsletter | August 4, 2026

08.04.26 -- Platform Strategies For Manufacturable Bispecific Antibodies

Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies

Manufacturing challenges have long limited the full potential of bispecific antibodies. Discover how an innovative engineering platform improves chain pairing, stability, expression, and product purity — enabling scalable production without compromising biological performance.

 

Redefining Bispecific Antibody Development With Structural Innovation And Enhanced Manufacturability

Bispecific antibodies (bsAbs) offer powerful therapeutic advantages, but their structural complexity creates significant development hurdles. Explore engineering strategies that improve molecular assembly, manufacturability, and product quality to accelerate clinical development.

 

Accelerating The Development And Production Of High-Quality Bispecific Antibodies

Able to simultaneously target multiple disease pathways, manufacturing bsAbs remains a major challenge. Learn how an advanced platform delivers precise chain pairing, higher productivity, and improved quality to speed development from discovery through production.

 

SOLUTIONS

 

Samsung Biologics — Your Program. Our Priority.

Samsung Biologics is a fully integrated, end-to-end CDMO partner offering seamless development and manufacturing services from cell line development to final aseptic fill/finish for biologics. Keeping the highest standards of commercialization in mind, we continue to expand our development portfolio and continue to offer the most optimized service to fit clients' needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.

 

•  Download Samsung Biologics Corporate Brochure

•  Download Samsung Biologics ADC Brochure

•  Download Samsung Biologics CDO Brochure

 

Request Information